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Case Reports

Treatment of Severe Metabolic Alkalosis with Continuous
Renal Replacement Therapy: Bicarbonate Kinetic
Equations of Clinical Value
Lenar Yessayan,*† Jerry Yee,* Stan Frinak,* David Kwon,‡ and Balazs Szamosfalvi*

Concomitant severe metabolic alkalosis, hypernatremia, and
kidney failure pose a therapeutic challenge. Hemodialysis to
correct azotemia and abnormal electrolytes results in rapid
correction of serum sodium, bicarbonate, and urea but presents a risk for dialysis disequilibrium and brain edema. We
describe a patient with Zollinger–Ellison syndrome with persistent encephalopathy, severe metabolic alkalosis (highest
bicarbonate 81 mEq/L), hypernatremia (sodium 157 mEq/L),
and kidney failure despite 30 hours of intravenous crystalloids and proton pump inhibitor. We used continuous renal
replacement therapy (RRT) with delivered hourly urea clearance of ~3 L/hour (24 hour sustained low efficiency dialysis with regional citrate anticoagulation protocol at blood
flow rate 60 ml/min and dialysate flow rate 400 ml/min). To
mitigate a pronounced decrease in plasma osmolality while
removing urea from this hypernatremic patient, dialysate
sodium was set to start at 155 mEq/L then at 150 mEq/L after
6 hours. Serum bicarbonate, urea, and sodium were slowly
corrected over 26 hours. This case demonstrates how to regulate and predict the systemic bicarbonate level using single
pool kinetic modeling during convective or diffusive RRT.
Kinetic modeling provides a valuable tool for systemic blood
pH control in future combined use of extracorporeal CO2
removal and continuous RRT systems. ASAIO Journal 2015;
61:e20–e25.

ZES patients, excessive gastrin secretion causes high gastric
acid output; with vomiting, nasogastric drainage, or acidic
diarrhea, severe “chloride depletion” metabolic alkalosis may
ensue.1 The treatment of metabolic alkalosis should aim to
reduce the ongoing acid losses from the stomach and reverse
the factors that impair renal bicarbonate excretion, namely
hypochloremia and hypokalemia.2–4 Gastric acid secretion
can be reduced in ZES by proton pump inhibitors (PPI), which
inhibit the hydrogen/potassium ATPase on the luminal surface
of parietal cells.5 Chloride repletion with an appropriate cation is necessary to reverse metabolic alkalosis. Concomitant
potassium depletion invariably occurs; this maintains alkalosis by a shift of protons into cells and enhanced urinary
hydrogen secretion through activation of the collecting tubule
H-K-ATPase.6 In cases of refractory severe alkalosis, a large
volume of hydrochloric acid infusion would be required rendering this option impractical and dangerous. This teaching
case illustrates continuous renal replacement therapy (CRRT)
prescription considerations in a patient with ZES and refractory severe metabolic alkalosis with delayed response to PPI,
hypernatremia, and azotemia refractory to volume repletion.
The biologic principles and required technology elements to
control systemic bicarbonate levels with CRRT are described
as this knowledge is necessary for near-automated or automated systemic blood pH control through future integration
of extracorporeal lung and kidney assist devices. Engineering
aspects of importance include:

Key Words: metabolic alkalosis, treatment, CRRT, renal
replacement therapy, dialysis, SLED, regional citrate
anticoagulation

1.  A mathematical model of bicarbonate kinetics was redeveloped in a format for easier use by clinicians. It follows
from the modeling that application to CRRT requires
elimination of circuit downtime which in turn requires
highly effective anticoagulation.
2.  Regional citrate anticoagulation (RCA) is used to keep
the membrane performance stable during 24 hour CRRT
which is indispensable for reliable small solute (e.g.,
bicarbonate) kinetics in diffusive blood purification.
3.  Online clearance measurements were incorporated and
feasibly obtained at a very low blood flow to detect any
effect of membrane fouling or access recirculation on
effective small solute dialysance every 2 hours, replacing
assumptions about dialysance with precise data.
4.  Regional citrate anticoagulation is provided with a protocol amenable to engineered, automated delivery and in
a way that there is virtually no citrate in the circuit blood
returning to the patient. This avoids variable bicarbonate

Z

ollinger–Ellison syndrome (ZES), caused by a gastrin-producing tumor, is characterized by refractory peptic ulcers,
severe diarrhea, and marked gastric acid hypersecretion. In
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generation which could result from a variable systemic
citrate metabolism during RCA and ensures applicability
of the approach in nonexpert hands in the future.
Case Report
A 21-year-old man with suspected ZES was admitted from an
outpatient clinic for worsening fatigue and generalized weakness since a recent emergent surgery for acute abdomen 55
days prior at another hospital. He had a 3 year history of persistent nausea, vomiting, abdominal pain, and diarrhea for which
he was admitted to the other hospital multiple times with no
clear diagnosis. Surgical history was significant for a perforated
duodenum for which he underwent primary duodenal repair
with omental patch and pyloric exclusion for perforated duodenal mass. He also had right hemicolectomy, a diverting loop
ileostomy, venting gastrostomy, and feeding jejunostomy. Medical history was otherwise negative including no known history
of alcohol abuse or illicit drug use. Medication use was pantoprazole 40 mg orally twice-daily. Information was not available
for either his baseline kidney function or his kidney function
before discharge from the other hospital.
His blood pressure was 109/63 mm Hg, heart rate 90 beats/min,
respiratory rate 10 breaths/min, temperature 37.5°, and pulse
oximetry 97% on room air. His weight was 50 kg. On physical
examination, his skin was normal in appearance and texture; a
right lower quadrant surgical scar was noted. His pupils were
equal and reactive to light bilaterally; he had dry oral mucosa.
No jugular venous distention was noted. Heart sounds were
normal with no murmurs, rubs, or gallops. Lungs were clear to
auscultation bilaterally. Bowel sounds were normal in quality
and intensity in all areas. No mass or splenomegaly noted.
He had a gastrostomy tube, a feeding jejunostomy tube, and
an ileostomy. Neurological examination revealed decreased
motor power, grade 3/5 in all extremities, and increased deep
tendon reflexes. He was not oriented to time, person, or place.
Glasgow Coma Scale was 11.
First set of serum laboratory studies were as follows: sodium,
157 mEq/L; potassium, 4.8 mEq/L; chloride, 78 mEq/L; bicarbonate, 58 mEq/L; serum urea nitrogen, 160 mg/dl; creatinine,
3 mg/dl; magnesium, 2.1 mg/dl; phosphorus, 7.6 mg/dl. Urine
chemistry on admission: sodium, 113 mEq/L; potassium, 40
mEq/L; chloride, <15 mEq/L; osmolality, 459 mOsm/kg. Urinalysis: pH, 8.5; protein, 30 mg/dl; negative for glucose,
ketones, and blood. First set of arterial blood gas analysis on
room air (24 hours from admission) showed pH 7.7, PaCO2 of
58 mm Hg, PaO2 of 81, bicarbonate 74 mEq/L. Gastrostomy
fluid analysis (24 hours from admission): sodium, <10 mEq/L;
potassium, 5 mEq/L; chloride, 158 mEq/L. Urine sediment
showed two granular casts per low power field. Kidney ultrasound was negative for hydronephrosis. Chest x-ray did not
reveal any acute cardiopulmonary process.
Upon admission, the patient was started on intravenous
crystalloids and intravenous PPI. However, despite 24 hours
of intravenous fluids and net positive fluid balance, the patient
had worsening metabolic alkalosis (highest HCO3 81 mEq/L)
severe alkalemia (pH 7.7) and worsening kidney function (creatinine, 3.5 mg/dl). This prompted a nephrology consultation
and a transfer to the intensive care unit.
Because of resistant life-threatening metabolic alkalosis,
worsening kidney function and persistent encephalopathy,

CRRT was started at ~30 hours from admission. We used continuous sustained low efficiency dialysis with RCA (24 hour
SLED-RCA) for 26 hours.7 Blood flow rate was set at 60 ml/min,
dialysate flow rate 400 ml/min, dialysate potassium at 4 mEq/L,
dialysate bicarbonate at 30 mEq/L, sodium at 155 mEq/L on
initiation, and at 150 mEq/L after 6 hours. Blood urea nitrogen
(BUN), serum sodium, and bicarbonate gradually corrected
to normal values. The patient’s mentation gradually improved
with no neurologic sequelae. He gradually recovered his kidney function over the next 7 days and his creatinine eventually
stabilized at about 0.7 mg/dl. The trends in serum chemistries
during the first 5 days of hospitalization are shown in Table 1.
Daily input and output during the first 4 days are shown in
Table 2.
Subsequent investigations showed a fasting gastrin level of
4,708 pg/ml consistent with ZES. Computed tomography on
day 7 showed a periportal mass and octreotide scan demonstrated intense radiotracer uptake in the head of the pancreas
region. After being medically and nutritionally optimized, on
day 35 after presentation, he underwent Whipple pancreaticoduodenectomy and takedown of loop ileostomy and feeding
jejunostomy. He was discharged home 3 weeks after surgery.
He was last seen 1 year postdischarge and was doing well with
no recurrence of his symptoms.
Discussion
In refractory cases of severe chloride depletion alkalosis (pH
> 7.55) or when immediate correction is necessary (e.g., cardiac arrhythmia or hepatic encephalopathy), treatment options
include the use of HCl infusion8,9 or renal replacement therapy
(RRT).10 Two other agents, ammonium chloride and arginine
hydrochloride, have been used for treatment of metabolic alkalosis. Life-threatening complications have been described with
both. The former can cause fatal hyperammonemia and is contraindicated in the presence of renal or hepatic insufficiency.11
The latter can cause severe hyperkalemia12 and its use is no
longer recommended.
Hydrochloric acid infusion should be used with caution as
devastating complications, such as tissue necrosis and death
have been reported.13,14 Administration is usually as a 0.1 normal (100 mEq/L) solution at a dose of 0.1–0.2 mmol/kg/hour.
Hydrochloric acid infusion requires a central venous catheter
and frequent monitoring of arterial blood gases and electrolytes.8,9 The total amount of HCl required (not accounting for
ongoing losses) can be estimated from the volume of distribution of bicarbonate (HCO3) in metabolic alkalosis (approximately equal to 50% of lean body weight in kg) times the
bicarbonate excess per liter (Equation 1 in Appendix).15
In our patient, neither the renal failure nor the metabolic alkalosis improved after 30 hours despite intravenous sodium chloride, potassium chloride repletion, and PPI infusion. Very large
volumes of 0.1 N HCl would have been required to fully correct
the alkalosis rendering this treatment option impractical with
the added danger of profound acute hyponatremia because of
free water load. The predicted base excess in our patient, based
on Equation 1, was about 1,300 mEq. Without accounting for
ongoing hydrogen losses in gastric secretions, the minimum
volume of 0.1 N HCl required to reverse the metabolic alkalosis
would have been about 13 L in this 50 kg patient.

Copyright © American Society of Artificial Internal Organs. Unauthorized reproduction of this article is prohibited.

e22

YESSAYAN et al.
Table 1.  Laboratory Data Before, During, and After Sustained Low Efficiency Dialysis with Citrate Anticoagulation

Time
(hours:mins)
0
5:03
6:35
15:04
20:15
26:28
28:30
34:28
38:15
46:00
50:20
53:45
54:00
58:49
74:20
83:05
92:09
98:20
110:15
124:15

Sodium (mEq/L)
157
158
161
158
159
160
158
156
150
147
152
151
145
146
144
143
145
148

Potassium
(mEq/L)

Chloride (mEq/L)

Bicarbonate
(mEq/L)

BUN (mg/dl)

Creatinine
(mg/dl)

Phosphorus
(mg/dl)

3.0
3.2
3.3
3.3
3.5
3.5

7.6
8.1
7.2
9.1
10.2

2.1
1.7
1.5
1.3
1.1

5.4
3.7
3.0
2.4
2.5

4.8
78
58
160
3.5
76
65
159
3
76
67
158
2.6
70
81
150
2.7
66
77
148
2.9
69
78
139
Start sustained low efficiency dialysis with citrate anticoagulation
4.6
97
52
70
4.6
106
42
46
5.6
108
35
35
4.8
110
29
19
4.2
114
32
17
End sustained low efficiency dialysis with citrate anticoagulation
4.1
113
32
20
2.6
107
32
29
2.6
104
35
26
3.0
105
32
21
4.0
107
33
18
3.4
108
30
21
4.1
97
41
25

1.4
1.6
1.6
1.5
1.5
1.2
1.2

Conversion factors for units: BUN in mg/dl to mmol/L, 0.357; serum creatinine mg/dl to μmol/L, ×88.8; phosphorus in mg/dl to mmol/L,
×0.323 mmol/L; no conversion is necessary for sodium in mEq/L and mmol/L, potassium in mEq/Land mmol/L, bicarbonate in mEq/L and
mmol/L, chloride in mEq/L and mmol/L.
BUN, blood urea nitrogen.

Because of the rare, yet potentially devastating complications that may be seen with HCl, any form of RRT may be
considered even in the absence of renal failure in those with
severe metabolic alkalosis refractory to treatment. However, in
those with marked renal failure, severe azotemia and/or hypernatremia, CRRT may be preferred because a rapid decline in
serum osmolality during hemodialysis may result in dialysis
disequilibrium, brain edema, and death.16 Figure 1 shows
expected BUN changes over time during four different RRT
modalities in this patient. As illustrated, hemodialysis and 12
hour SLED will result in rapid decrease in BUN and are not
advisable. With CRRT (either continuous venovenous hemofiltration (CVVH) or 24 hour SLED-RCA), rapid osmolar shifts
could be avoided while delivering a minimum daily urea clearance of 25 ml/kg/hour. Moreover, any reduction in a hypernatremic patient’s serum tonicity during CRRT can be mitigated

by increasing the replacement fluid (RF) or dialysate sodium
concentration. Continuous renal replacement therapy with
systemic anticoagulation might have been detrimental in this
patient with suspected ZES, possible multiple peptic ulcers and
the potential need for surgery.
Single Pool Kinetic Modeling of Bicarbonate Mass Balance
Accurate predictions of the magnitudes of bicarbonate loss
during RRT require complex quantification of bicarbonate mass
balance across the dialyzer membrane.17 However, bicarbonate
single pool fixed volume kinetic predictions of clinical value
could be used to estimate serum bicarbonate concentration at
time = t during RRT (Equation 2 in Appendix).18 According to the
equation, the value of serum bicarbonate during CRRT is conditioned by a number of variables, including serum bicarbonate

Table 2.  Daily Input and Output During the 4 Four Days of Admission

NS (ml) with 20 mEq/L KCl
½ NS (ml) with 20 mEq/L KCL
½ NS (ml)
NS (ml)
D5 ½ NS (ml)
KCL (IV; ml)
Sodium phosphate (ml)
Oral-free water (ml)
Packed RBC (units)
TPN (ml)
Pantoprazole (NS; ml)
Gastrostomy (ml)
Ileostomy (ml)
Urine output (ml)

First 30 Hours

Day 2

Day 3

Day 4

1,850
2,700
2,825
1,800
600
728
140
6,278
150
600

1,000
1,244
1,750
400
240
2,695
1,000

980
1,800
2,500
1,000
100
2 units
240
2,195
1,080

2,117
2,250
1,600
195
240
4,390
1,670

D5, 5% dextrose; KCL, potassium chloride; NS, normal saline; RBC, red blood cells; TPN, total parenteral nutrition.
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calculated using standard equations that describe the relation of bicarbonate dialysance as a function of dialyzer solute mass transfer coefficient (KoA), bicarbonate effective water
flow (QEB-HCO 3 ), and dialysate flow rate (Qd).17,18 In machines
equipped with conductivity monitors that measure and display
effective ionic dialysance (Kecn), the bicarbonate dialysance
can be estimated to be 90−95% of Kecn.
Estimation of Bicarbonate Generation

Figure 1. Expected blood urea nitrogen over time using hemodialysis with delivered clearance (K) of 250 ml/min, SLED with K of
150 ml/min, SLED-RCA with K of 50 ml/min, and CVVH with delivered K of 21 ml/min (25 ml/kg/hour). CVVH, continuous venovenous
hemofiltration; SLED-RCA, sustained low efficiency dialysis with
regional citrate anticoagulation.

concentration at start of CRRT [HCO3]i, fresh dialysate bicarbonate concentration [dHCO3], volume of distribution of bicarbonate (V), bicarbonate dialysance (D), elapsed time on RRT (t),
net body bicarbonate generation rate (G), and the Donnan-factor (α) across the dialyzer membrane. The Donnan factor takes
into account that the diffusive gradient of bicarbonate across
the dialysis membrane not only depends on the concentration
gradient but also on the electrical gradient. The presence in the
plasma of nondiffusible plasma proteins promotes ejection of
bicarbonate ions across the dialysis membrane. Therefore, the
value of serum bicarbonate at equilibrium is not equal to dialysate bicarbonate. The ratio α = dHCO3/HCO3 at equilibrium is
Gibbs Donnan coefficient. This value is higher than 1.0 but less
than 1.1 for monovalent anions.19
If all these variables are known, then it is possible: 1) to predict
the concentration of bicarbonate at time = t on RRT (Equation 2);
and 2) the net bicarbonate removed by the dialyzer at time = t
on RRT (Equation 3 in Appendix). Many of these variables are
already known at the start of RRT. However, three of these variables need to be estimated: volume of distribution of bicarbonate (V) which is approximately 40% to 50% of lean body weight
at plasma bicarbonate concentration greater than 30 mEq/L,20
bicarbonate dialysance (D), and net bicarbonate generation (G).
Estimation of Bicarbonate Dialysance
Bicarbonate dialysance (D) is slightly lower than urea clearance. It may be estimated for both convective and diffusive RRT
modalities using the same equations and methods for measurement of urea clearance. For convective treatments with any
combination of pre and/or postdilution CVVH, bicarbonate
dialysance (D) can be estimated (Equation 4 in Appendix).21
The determinants of bicarbonate dialysance (D) are the bicarbonate sieving coefficient (SHCO 3) which is almost equal to one,
predilution RF flow rate (Qpre), postdilution RF flow rate (Qpost),
ultrafiltration rate (Quf), effective blood water flow rate for bicarbonate (QEB-HCO 3 ) which is about 94−88% of that of urea effective blood water flow between HCT levels of 24−45 mg/dl.18
For diffusive treatments, bicarbonate dialysance (D) is
approximately 85% of urea clearance.18 It can also be

To complete kinetic modeling of systemic bicarbonate, it
is necessary to estimate systemic bicarbonate generation, G.
Under normal conditions, the release of acid equivalents from
metabolism exceeds the amounts of base released concomitantly (bicarbonate from organic acid salts), known as net acid
production and must be excreted by the kidney to maintain
acid–base balance. A small amount of bicarbonate (approximately 30 mmol) appears in stool every day and contributes
to daily acid production.22 On a typical western diet, the net
daily acid production is around 1 mEq/kg/day. In a patient with
high gastric output and acid loss, bicarbonate production can
far exceed daily acid production. The alkaline urine’s impact
on bicarbonate kinetic modeling (G) can be neglected when
overall urine volume is low.
Estimation or measurement of gastric content’s pH and
hourly losses is needed to estimate bicarbonate generation.
For example, in untreated ZES, gastric pH is less than two in
almost all patients and can be less than one in almost onethird.23 Near 31.6, 100, and 316 mEq of protons may be lost
per each liter of gastric output at gastric pH 1.5, 1, and 0.5,
respectively. Information on G may not be readily available
to the treating physician at the time for treatment decisions.
However, in such scenarios, the clinician will consider more
than one scenario or perhaps two extremes. For example, we
entertained two possibilities of bicarbonate generation rates
(G). First, complete inhibition of bicarbonate generation (G =
0) by PPI by the time of initiation of RRT. Second, ongoing
generation of bicarbonate at +G = 16 mmol/hour (secondary to
~400 mEq of hydrogen ion per day in 2.5–3 L of gastric fluid at
150 mEq/L). Finally, the physician may need to consider the
effect of urinary bicarbonate on the net bicarbonate generation
under conditions where urine bicarbonate losses are nonnegligible. In our case, the total urine bicarbonate losses could not
have exceeded the total urine (nonammonium) cations losses
(150 mEq on day 2 and 75 mEq in the first 30 hours). These
amounts were clearly insufficient to cause a rapid enough
improvement in the patient’s severe alkalosis. Figure 2 shows
the impact of different levels of G on the estimated plasma
HCO3 at any time t in the same patient. In addition to the bicarbonate generation considerations discussed above, the figure
also includes a hypothetical model that shows the impact of a
sudden massive production of lactic acid, because of perforation and abdominal sepsis, on predicted bicarbonate during
RRT. The hydrogen ions generated will cause disappearance
of bicarbonate (-G) from the extracellular space and alter the
prediction of the model.
In patients with severe alkalemia, it is important to avoid
CRRT prescriptions that introduce a large amount of organic
anions (acetate, lactate, or citrate) into the CRRT circuit return
blood flow. The liver metabolism of such anions to bicarbonate may be highly variable and unpredictable in intensive care
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unit patients rendering systemic bicarbonate level prediction
and control impossible. The CRRT return blood in our 24 hour
SLED-RCA is acetate- and lactate-free with a citrate level of
0.8–1.1 mmol/L eliminating this confounding factor.
For our patient, the goal was to rescue the patient from such
severe alkalosis by removing more than 50% of the excess
bicarbonate, and to correct the uremia while avoiding rapid
decrease in serum osmolality. CVVH with customized bicarbonate fluid bags could have achieved these goals. Using
Equation 3, the net bicarbonate removed at any time could be
estimated. Our patient had a predialysis body weight of 50 kg.
We estimated he had an approximate of ~25 L. Initial serum
contained bicarbonate of 78 mEq/L. CVVH treatment for 24
hours with blood flow rate (Qb) at 300 ml/min, predilution RF
flow rate (Qpre) at 1.25 L/h, and no ultrafiltration would have
delivered urea clearance of ~25 ml/kg/hour and a bicarbonate
dialysance of ~1.2 L/h (Equation 4). Assuming complete inhibition of ongoing acid production and using RF bicarbonate
concentration 35 mEq/L, near 750 mEq of bicarbonate would
be removed by 24 hours of CVVH treatment.
We used the 24 hour SLED-RCA protocol. Blood flow rate
is set at 60 ml/min and dialysate flow rate at 400 ml/min. The
system also provides indirect measurements of delivered
urea clearance by online clearance measurement of effective ionic dialysance (Kecn). The delivered urea clearance is
fixed at ~3 L/h resulting in a small solute clearance in the range
of 25−45 ml/kg/hour for patients weighing between 120 and
65 kg, respectively. To prevent rapid changes in plasma osmolarity at delivered CRRT dose of 60 ml/kg/hour in this 50 kg
patient, dialysate sodium was set at 155 mEq/L on initiation
and at 150 mEq/L after 6 hours. The serum sodium was maintained at ≥155 mEq/L during the first 10 hours and ≥150 mEq/L
until the end of treatment (Table 1). The patient’s bicarbonate

corrected by 24 hour SLED-RCA treatment. Dialysate bicarbonate was set 30 mEq/L and bicarbonate dialysance was ~50 ml/
min. The kinetic bicarbonate model (Equation 2) demonstrated
an acceptable prediction with the observed values (Figure 2).
Undoubtedly, severe derangements in plasma solutes where
mathematical modeling may be valuable in treatment prescription are infrequent. Moreover, a substantial amount of
the information may not be readily available to the treating
physician in the time required to make treatment decision.
However, the capacity to quantitatively express biochemical
processes and to estimate these when unavailable renders
mathematical modeling a handy tool for better management
of patients. For example, the time needed to achieve a desired
therapeutic goal with a particular prescription may be anticipated. This may be helpful as decisions on other therapeutic
plans (i.e., timing of a possible surgery, decision whether to
use HCl) in a critically ill patient with severe alkalosis may be
affected by the anticipated degree and timing of correction.
Modeling also allows for predictable modifications in prescription in response to altered biochemical changes to achieve a
desired change.
We believe the calculations from the model described
could be automated and incorporated into CRRT system software. Such an implementation could prove clinically both
practical and indispensable in future multiorgan support with
combined extracorporeal CO2 removal and CRRT affording
precise, rapid control of both systemic CO2 and bicarbonate
and hence, ultimately, of systemic blood pH. Application of
such a model in acid–base disorders requires further testing
for endorsed use.
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Appendix
HCO3 excess (mEq ) = 0.5×LBW × ([HCO3] − 24),
where LBW is lean body weight (kg); [HCO3] is serum bicarbonate
concentration (mEq/L).

[ HCO3] (t ) = [dHCO3] +  [ HCO3] i −
1
α

 − Dt
×e V



Figure 2. The impact of different levels of bicarbonate G on the
estimated systemic serum HCO3 at any time t in our patient. One
state is where net G is positive because of ongoing acid vomiting.
A second state has a net G of zero where there is near complete
suppression of bicarbonate generation with continuous intravenous
proton pump inhibitor administration. A third hypothetical state has
a negative G of high magnitude such as abdominal sepsis because
of viscus perforation where net lactic acid production rate may be
45 mEq/hour.



− Dt


 + G / D × 1 − e V





1

[dHCO3] 
α

(2)


,



where [HCO3] (t) is bicarbonate concentration at time = t during
RRT (mEq/L); [HCO3]i is the initial serum bicarbonate concentration
(mEq/L); [dHCO3] is fresh dialysate bicarbonate concentration (mEq/L);
D is bicarbonate dialysance (L/hour); V is total body water (L); t is time
since start of RRT (hours); G is net body bicarbonate generation rate
(mEq/hour); and α Donnan factor for bicarbonate.
HCO3 removed by dialyzer (mEq ) =
− Dt

1
 
V ×  [ HCO3] i − [ dHCO3] − G / D  × 1 − e V
α

 


  + G × t,



(3)
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QEB-HCO3
D =
× Qpre + Qpost + Quf ,
×S
 QEB-HCO3 + Qpre  HCO3



(

)

(4)

where QEB-HCO3 is the effective blood water flow rate for bicarbonate; Qpre predilution RF flow rate; Qpost postdilution RF flow rate; Quf
ultrafiltration rate; and SHCO3 bicarbonate sieving coefficient.
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